• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Consumer Cyclical·000972.SZ
Share

Chalkis Health Industry Co., Ltd Stocks

CN¥ 4.11Last Updated 12.10.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 481.76M

CN¥ 4.11
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Chalkis Health Industry Co., Ltd. operates internationally, specializing in the cultivation, processing, and sale of tomatoes. Its diverse product portfolio includes concentrated tomato paste, available in drums and wooden bins; prepared tomato varieties such as peeled, diced, and canned goods; innovative tomato-derived products like fiber sheets and seed oil; and health supplements, specifically lycopene capsules. The company, headquartered in Urumqi, China, adopted its current name, Chalkis Health Industry Co., Ltd., in May 2016, having previously been known as Xinjiang Chalkis Co., Ltd.

Company Valuation

Overvalued
2/7

Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is overvalued on EV/EBITDA, underpriced on P/FC.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 19:20

Is it time to buy stocks? Goldman Sachs has upgraded its recommendation for the next three months

12.10.2026 18:58

Oppenheimer recommends buying Fastly stock ahead of the earnings report and the release of the iconic game GTA

12.10.2026 18:03

Shares of Nebius' competitor surged following news of a contract with Anthropic

12.10.2026 17:57

China's CXMT has unsettled investors in Micron and Samsung, causing their stock prices to fall. What's going on?

12.10.2026 16:53

Jennifer Garner's company could see its stock price rise by 50%: Freedom has identified unaccounted-for growth drivers

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026